Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
manilatimes1d
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Silexion Therapeutics (SLXN) Gets a Buy from Maxim Group
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...
bovnews1d
Silexion Therapeutics Corp (SLXN) Stock: A Deeper Look at Its True Potential
Silexion Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -97.05%. The profit margin, also known as the revenue ratio or gross profit ...
Silexion Therapeutics reports preclinical data for SIL-204
Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...
Silexion reports breakthrough in KRAS cancer therapy
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...
Stocktwits on MSN53m
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why
Biotech stocks remain a hot sector for retail traders on Stocktwits, which collectively boast over 3.45 million followers. In ...